| Ytd | 143.65% | |
| 1y | 37.14% |
| Open | 9.83 | Prev Close | 9.84 | Low | 9.53 | High | 10.25 | Mkt Cap | 291.53M |
| Vol | 31.58K | Avg Vol | 80.68K | EPS | -0.28 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 8.80 | 200-d Avg | 5.17 | 1yr Est | 0.00 |
TTRX News
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized t
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approxi
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, n
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its
Turn Therapeutics, Inc. (NASDAQ:TTRX) on Tuesday said a planned interim analysis of its adaptive Pha
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a br
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expa
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, n
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, l
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the anal
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b
Turn Therapeutics Inc. (NASDAQ: TTRX - Get Free Report)'s share price traded up 6% during trading on
Athersys (NASDAQ: ATHX - Get Free Report) and Turn Therapeutics (NASDAQ: TTRX - Get Free Report) are
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology c
Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and m
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analy
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechn
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock
Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges
Turn Therapeutics' shares surged 134% in after-hours trading following its Nasdaq debut, despite